The Role of Gut Microbiota in Liver Disease Development and Treatment

Overview

Journal Liver Res

Date 2020 May 29

PMID 32461811

Citations 22

Authors

Lijun Wang

Yu-Jui Yvonne Wan

Affiliations

Soon will be listed here.

Abstract

Liver cancer is the sixth most common cancer worldwide, and the third most common cause of cancer-related death. Hepatocellular carcinoma (HCC), which accounts for more than 90% of primary liver cancers, is an important public health problem. In addition to cirrhosis caused by hepatitis B viral (HBV) or hepatitis C viral (HCV) infection, non-alcoholic fatty liver disease (NAFLD) is becoming a major risk factor for liver cancer because of the prevalence of obesity. Non-alcoholic steatohepatitis (NASH) will likely become the leading indication for liver transplantation in the future. It is well recognized that gut microbiota is a key environmental factor in the pathogenesis of liver disease and cancer. The interplay between gut microbiota and liver disease has been investigated in animal and clinical studies. In this article, we summarize the roles of gut microbiota in the development of liver disease as well as gut microbiota-targeted therapies.

Citing Articles

Tetrahydrocurcumin Alleviates Metabolic Dysfunction-Associated Steatohepatitis in Mice by Regulating Serum Lipids, Bile Acids, and Gut Microbiota.

Peng S, Meng M, Luo P, Liu J, Wang J, Chen Y Int J Mol Sci. 2025; 26(3).

PMID: 39940665 PMC: 11816436. DOI: 10.3390/ijms26030895.

Gut Microbiota-microRNA Interactions and Obesity Pathophysiology: A Systematic Review of Integrated Studies.

Azari H, George M, Albracht-Schulte K Int J Mol Sci. 2024; 25(23).

PMID: 39684547 PMC: 11640985. DOI: 10.3390/ijms252312836.

Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma.

Setayesh T, Hu Y, Vaziri F, Chen X, Lai J, Wei D Acta Pharm Sin B. 2024; 14(1):292-303.

PMID: 38261802 PMC: 10793093. DOI: 10.1016/j.apsb.2023.10.010.

From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes.

Widjaja F, Rietjens I Biomedicines. 2023; 11(10).

PMID: 37893032 PMC: 10603957. DOI: 10.3390/biomedicines11102658.

Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease.

Ganesan R, Gupta H, Jeong J, Sharma S, Won S, Oh K Hepatol Int. 2023; 18(2):486-499.

PMID: 37000389 DOI: 10.1007/s12072-023-10518-9.

References

Walters W, Xu Z, Knight R . Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett. 2014; 588(22):4223-33. PMC: 5050012. DOI: 10.1016/j.febslet.2014.09.039. View

Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A . Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062.e5. PMC: 5502730. DOI: 10.1016/j.cmet.2017.04.001. View

Takeshita T, Suzuki N, Nakano Y, Yasui M, Yoneda M, Shimazaki Y . Discrimination of the oral microbiota associated with high hydrogen sulfide and methyl mercaptan production. Sci Rep. 2012; 2:215. PMC: 3253589. DOI: 10.1038/srep00215. View

Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View

Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J . Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010; 16(24):2978-90. PMC: 2890937. DOI: 10.3748/wjg.v16.i24.2978. View

Neyrinck A, Possemiers S, Verstraete W, De Backer F, Cani P, Delzenne N . Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. J Nutr Biochem. 2011; 23(1):51-9. DOI: 10.1016/j.jnutbio.2010.10.008. View

Huang Y, Fan X, Wang Z, Zhou J, Tian X, Li N . Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J Clin Pathol. 2004; 57(12):1273-7. PMC: 1770525. DOI: 10.1136/jcp.2004.018556. View

Rafiei R, Bemanian M, Rafiei F, Bahrami M, Fooladi L, Ebrahimi G . Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth. Rom J Intern Med. 2017; 56(2):85-89. DOI: 10.1515/rjim-2017-0042. View

Chen J, Wang R, Li X, Wang R . Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br J Nutr. 2011; 107(10):1429-34. DOI: 10.1017/S0007114511004491. View

10.

Brandi G, De Lorenzo S, Candela M, Pantaleo M, Bellentani S, Tovoli F . Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis. 2017; 38(3):231-240. DOI: 10.1093/carcin/bgx007. View

11.

Lewis S, Burmeister S . A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids. Eur J Clin Nutr. 2005; 59(6):776-80. DOI: 10.1038/sj.ejcn.1602139. View

12.

Inagaki T, Moschetta A, Lee Y, Peng L, Zhao G, Downes M . Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006; 103(10):3920-5. PMC: 1450165. DOI: 10.1073/pnas.0509592103. View

13.

Li J, Sung C, Lee N, Ni Y, Pihlajamaki J, Panagiotou G . Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A. 2016; 113(9):E1306-15. PMC: 4780612. DOI: 10.1073/pnas.1518189113. View

14.

Mollica M, Raso G, Cavaliere G, Trinchese G, De Filippo C, Aceto S . Butyrate Regulates Liver Mitochondrial Function, Efficiency, and Dynamics in Insulin-Resistant Obese Mice. Diabetes. 2017; 66(5):1405-1418. DOI: 10.2337/db16-0924. View

15.

Jegatheesan P, Beutheu S, Ventura G, Sarfati G, Nubret E, Kapel N . Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease. Clin Nutr. 2015; 35(1):175-182. DOI: 10.1016/j.clnu.2015.01.021. View

16.

Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L . Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep. 2016; 6:32002. PMC: 4994089. DOI: 10.1038/srep32002. View

17.

Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L . Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014; 513(7516):59-64. DOI: 10.1038/nature13568. View

18.

Safe S, Papineni S, Chintharlapalli S . Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Lett. 2008; 269(2):326-38. PMC: 2574232. DOI: 10.1016/j.canlet.2008.04.021. View

19.

Nilsson H, Mulchandani R, Tranberg K, Stenram U, Wadstrom T . Helicobacter species identified in liver from patients with cholangiocarcinoma and hepatocellular carcinoma. Gastroenterology. 2001; 120(1):323-4. DOI: 10.1053/gast.2001.21382. View

20.

Yamada S, Takashina Y, Watanabe M, Nagamine R, Saito Y, Kamada N . Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget. 2018; 9(11):9925-9939. PMC: 5839411. DOI: 10.18632/oncotarget.24066. View